Sarepta refuses the request of the FDA to stop sending the muscle dirty dystrophy Elestidys

The regulator had asked Sarepta Therapeutics to stop all the expeditions of his therapy, elessys, after three patients had died of hepatic insufficiency after taking it or similar treatment.